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ABSTRACT
Abnormal DNA methylation is observed in certain
promotersofneoplasticcells,althoughthelikelihood
of methylation for each individual promoter varies.
Simultaneous analysis of many promoters in the
same sample can allow use of statistical methods
for identification of neoplasia. Here we describe
an assay for such analysis, based on digestion of
genomic DNA with methylation-sensitive restriction
enzyme and multiplexed PCR with gene-specific
primers (MSRE-PCR). MSRE-PCR includes extensive
digestion of genomic DNA (uncut fragments cannot
beidentifiedbyPCR),canbeappliedtodilutesamples
(<1pg/ml),requireslimitedamountofstartingmaterial
(42 pg or genomic equivalent of seven cells) and can
identify methylation in a heterogeneous mix contain-
ing <2% of cells with methylated fragments. When
applied to 53 promoters of breast cancer cell lines
MCF-7, MDA-MB-231 and T47D, MSRE-PCR correctly
identified the methylation status of genes analyzed
by other techniques. For selected genes results of
MSRE-PCR were confirmed by methylation-specific
PCR and bisulfite sequencing. The assay can be
configured for any number of desired targets in any
user-defined set of genes.
INTRODUCTION
Tumor-speciﬁc changes in DNA methylation have been
observedinmanydifferentmalignanciesandarefrequentlydes-
cribed as global hypomethylation combined with local hyper-
methylation [reviewed in (1–5)]. Global hypomethylation (6)
is linked to genomic instability of a tumor (7), whereas
hypermethylation of speciﬁc genes correlates with their silen-
cing (8) and can induce point mutations owing to spontaneous
deamination of 5me-C (transversion C>T) (9). Silencing of a
tumor suppressor gene can lead to enhanced transformation
and increased tumor growth through disruption of the normal
regulatory mechanisms of the affected cell (10,11). Given that
DNA methylation is a speciﬁc chemical modiﬁcation of one
of the most stable biological macromolecules, the DNA
methylation status of a selected gene is an attractive diagnostic
biomarker (12), and the potential of DNA methylation for
early diagnosis, outcome prediction and therapy adjustments
is well recognized (13). Unfortunately, no known gene is
always methylated in a given tumor: the highest frequency
of methylation reported thus far is in the promoter of 14-3-3s
[stratiﬁn; methylated in 96% of breast carcinomas and in 38%
of atypical hyperplasias (14)], thus simultaneous rapid and
high-throughput evaluation of methylation events in many
promoters can increase the diagnostic value of promoter
methylation, increasing the reliability of cancer detection (15).
In this paper we describe a procedure of methylation-
sensitive restriction enzyme digestion PCR (MSRE-PCR),
which can be used for rapid detection of DNA methylation
in multiple fragments simultaneously. This procedure is based
on extensive digestion of genomic DNA with methylation-
sensitive restriction enzyme (MSRE) followed by multiplexed
PCR ampliﬁcation of user-deﬁned genes using gene-speciﬁc
primers. Although elimination of unmethylated fragments
from the pool of potential PCR templates by MSRE digestion
has been tried before (16,17), the requirements for high spe-
ciﬁcity and sensitivity of the assay present substantial prob-
lems that have been resolved in MSRE-PCR, which allows
analysis of DNA methylation in a genomic equivalent of
seven cells and can reliably detect methylation present in
<2% of the sample.
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Cell culture
MCF-7 and T47D cells were maintained in phenol red con-
taining RPMI 1640 supplemented with 10% FBS, 100 mg/ml
streptomycin, 100 U/ml penicillin, 6 ng/ml bovine insulin,
2m ML-glutamine and 100 mM non-essential amino acids.
Estrogen receptor-negative MDA-MB-231 cells were main-
tained in phenol red-containing MEM with 10% CBS
and the same additives as MCF-7 and T47D. All materials
were obtained from Invitrogen (Carlsbad, CA). The uPA,
E-cadherin, SRBC and calcitonin cDNA containing plasmids
were obtained from Invitrogen or the American Type Culture
Collection (Rockville, MD).
DNA isolation
Genomic DNA was isolated from tissue culture cells using the
DNeasy Tissue Kit (Qiagen, Valencia, CA), and DNA con-
centration was determined using DyNA Quant 2000 (Hoefer,
Amersham Biosciences, Piscataway, NJ).
DNA digestion and purification
Digestions were performed with Hin6I (recognition site
GCGC; Fermentas, Hanover, NJ). Typically, 500 ng of
genomic DNAwere mixed with 100 pg of pUC19 anddigested
with 40 U of the enzyme at 37C for 72 h under a layer
of mineral oil; the ﬁnal volume of the reaction was 50 mL.
Control samples were treated in the same way but without the
addition of the enzyme. After incubation, digested samples
were puriﬁed using DNA Clean Up and Concentrator-5
(Zymo Research, Orange, CA) and eluted in 100 mLo f
TRIS–EDTA. Control samples were ethanol precipitated
and dissolved in 100 mL of TRIS–EDTA.
Primer design and PCR amplification
Genomic fragments containing at least two but no more than
six Hin6I recognition sites and located within corresponding
CpG islands were selected for ampliﬁcation. Primer design
was done using Clone Manager Suite 7, version 7.01, with
Primer Designer 5, version 5.01 (Scientiﬁc and Educational
Software, Durham, NC). Primers used in this study are
available upon request.
KlenTaq1 was from AB Peptides (St Louis, MO) or DNA
Polymerase Technology (St Louis, MO) and was used at 0.2 U
per reaction. The buffer supplied with the enzyme was used
without further adjustments, except the addition of betaine
(Sigma, St Louis, MO) to 1.5 M ﬁnal for each reaction; dNTPs
(Sigma, St Louis, MO) were added to 0.2 mM; primers
were used at 0.4 mM each. An ABI 9600 thermocycler was
programmed for touch-down PCR (94C, 40 s; Ta
C, 40 s;
72C, 60 s), with Ta starting at 65C and reducing 2C every
two cycles to 55C followed by 35 cycles with Ta at 55C.
Final extension was for 10 min at 72C and incubation was
at 4C. Finally, 3 ml of the product were loaded onto 2%
agarose or 12% polyacrylamide and visualized after ethidium
bromide staining.
Northern blot confirmation
RNAextractionandnorthernblotwereperformedasdescribed
elsewhere (18).
Methylation-specific PCR
Methylation-speciﬁc PCR (19) was performed using
the CpGenome Modiﬁcation kit (Intergene–Serologicals,
Norcross, GA). MethPrimer (20) was used for primer design;
primer sequences are available upon request. PCR conditions
were as described elsewhere (21).
Bisulfite sequencing
Bisulﬁte sequencing was performed using bisulﬁte-modiﬁed
DNA (see above) and sequencing primers Fcalc (GAATTTT-
AAGTTAGAGTTTTTGTTTT) and Rcalc (AATTTCAATTC-
CACTATACCTAAAC), designed using MethPrimer (20).
PCR conditions were as described elsewhere (21). PCR frag-
ments were cloned into pGEM-T-Easy (Promega, Madison,
WI)asdescribedbythemanufacturer,and10individualclones
were sequenced using M13 primer. No fewer than six clones
were evaluated for CpG>TpG conversion of CpG sites.
RESULTS
The overall schema of the experiment is presented in
Figure 1A. Successful extensive digestion of DNA in the
sample is a critical element of the procedure, and to monitor
thisprocess weusedaninternalsubstrate(pUC19DNA)added
before digestion to control samples and samples incubated
with the enzyme. After puriﬁcation of digested DNA a sep-
arate PCR reaction was performed using pUC19-speciﬁc pri-
mers ﬂanking two GCGC sites in pUC19. Results of this PCR
(35 cycles) served as a quality control for the digestion pro-
cedure;atypicalexampleisshowninFigure1B, wherecontrol
(no enzyme) incubations allow formation of PCR product
(template is preserved), whereas samples incubated with the
enzyme do not (template is destroyed). A separate control—
incubation of in vitro methylated pUC19 DNA with the
enzyme—invariably produced ampliﬁable DNA, thus con-
ﬁrming the purity of the restriction enzyme (data not shown).
Once the sample passed this quality control it was used for
PCR with gene-speciﬁc primers designed to amplify genomic
fragments located within CpG islands (Figure 1C). Multiplex
PCR—4 fragments for agarose gel (Figure 1C) and up to
12 fragments for polyacrylamide gel analysis (data not
shown)—was used; gel resolution and the overall requirement
for size difference within ampliﬁed fragments appeared to be
the limiting factors for further multiplexing. Since the absence
of PCR products in digested samples can indicate either its
sensitivity to the enzyme or the failure of a speciﬁc primer
pair, bands in the control sample were compared with bands in
the matching digested sample, and only samples producing
expected bands in the undigested control were scored.
The assay can be used with small amounts of DNA: 20 pg
(the genomic equivalent of three cells) were sufﬁcient for
PCR analysis (Figure 1D, lane 3). Digestion parameters were
optimized for small amounts of DNA; in selected conditions
we always observed successful digestion even when DNA
concentration was extremely low (Figure 1D; lanes 4–6). Sig-
niﬁcantly, a 100-fold increase in the amount of digested
genomic DNA did not result in formation of PCR product for
estrogenreceptorpromotera(Figure1D;lanes4–6),muchless
in formation of the product to the extent seen in undigested
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lanes 1–3). Apparently, digestion eliminated at least 99% of
unmethylated template (20 pg versus 2 ng). Quantitative PCR
results conﬁrmed this result (data not shown).
MSRE-PCR can produce three types of outcomes (Table 1):
methylation or its absence in a given region is clearly deﬁned
by the readout, whereas the absence of a band in the control
(undigested) sample can indicate a deletion of a corresponding
region or a single nucleotide polymorphism within the primer-
binding sequence. Such regions can then be tested by inde-
pendent methods.
Validation of MSRE-PCR has been carried out by compar-
ison of methylation data for breast cancer cell lines with pre-
viously published results obtained with alternative techniques
(Table 2). In the vast majority of cases MSRE-PCR and other
techniques gave identical results, conﬁrming MSRE-PCR per-
formance. In several cases the differences can be attributed to
variations in sequences examined (ﬁrst exon versus promoter)
or to clonal variability (see Discussion).
Besidescomparison ofour results with previouslypublished
data (Table 2) we validated MSRE-PCR results with three
independent assays: methylation-speciﬁc PCR (MSP) (19),
bisulﬁte sequencing (22) and northern blot analysis of gene
expression (Figure 2). Primers for MSP and bisulﬁte
sequencing were designed to analyze a fragment within the
MSRE-PCR-ampliﬁed region.
MSP analysis conﬁrmed MSRE-PCR data for all fragments
tested (compare Table 2 and Figure 2A). Another conﬁrmation
was obtainedwith direct bisulﬁte sequencing(22) ofcalcitonin
promoter in T47D and MCF-7 cells (compare Table 2 and
Figure 2B). For MCF-7 cells the probability of methylated
cytosine in the region analyzed is very high (90–100% for
six CpG dinucleotides located within Hin6I sites), suggesting
that this template would be resistant to Hin6I treatment. At the
same time, in good agreement with MSRE-PCR data in T47D
cells, this region is signiﬁcantly less methylated (the probab-
ility of cytosine methylation within Hin6I site can reach 0%,
indicating that all fragments will be cut at least once).
Northern blot analysis provided another conﬁrmation of
MSRE-PCR data, indicating a reverse correlation between
mRNA expression and promoter methylation (Table 2 and
Figure 2C). Importantly, although methylation of the promoter
strongly correlates with the absence of expression, the reverse
is not necessarily true, since negative transcriptional control
can be linked to mechanisms other than methylation. This is
the case with calcitonin: methylation of its promoter explains
the absence of the message in MCF-7 and MDA-MB-231,
whereas silencing in T47D is probably achieved through
different mechanisms.
Sensitivity of the assay was tested with a mixture of DNA
from T47D and MCF-7 cells (Figure 3), starting with digestion
A
B
D
C
Figure 1. Methylation-sensitive restriction enzyme digestion and PCR with
gene-specific primers (MSRE-PCR). (A) Schema of the experiment. Genomic
DNA is mixed with pUC19 DNA (internal control) and separated into two
aliquots. One of them is treated with Hin6I, and the other is incubated in
identical conditions but without the enzyme. Quality control PCR is then
performed with pUC19-specific primers, and successfully digested samples
areusedforPCRwithgene-specificprimers.(B)Anexampleofqualitycontrol
PCRusingprimersforpUC19.Lanes1,3and5containPCRproductsobtained
withcontrol(undigested) DNA.Lanes2, 4and6 wereloadedwitha PCRreac-
tion mixture performed with experimental (digested) DNA. All three samples
(MCF-7, T47D and MDA-MB-231) successfully passed quality control.
(C) An example of MSRE-PCR. Gene-specific primers for p15Ink4b,
p16Ink4a, p27Kip1 and BRCA1 were used in a tetraplexed format. Lanes 1,
3 and 5 contain PCR products from control (undigested)DNA; lanes 2, 4 and 6
containPCRproductsfromexperimental(digested)DNAfromMDA-MB-231
(lanes1and2),MCF-7(lanes3and4)andT47D(lanes5and6).Theabsenceof
p15Ink4b-specific and p16Ink4a-specific fragments in both undigested (con-
trol) and digested (experimental) samples for MDA-MB-231 and MCF-7
(lanes 1, 3 and 2, 4) suggests that both genes located in 9p21 are deleted.
(D) MSRE-PCR can be performed with 200 pg of genomic DNA. Minimal
amounts of DNA are required for digestion and PCR amplification was estab-
lishedusingDNAfromT47Dcells.DigestionwithHin6Iwasdoneusing20ng
(lanes 1 and4), 2 ng (lanes 2 and5) and 0.2 ng (lanes 3 and6). One-tenthof the
digestion mixture was used for PCR, so the amount of the template is 2 ng
(lanes 1 and 4), 0.2 ng (lanes 2 and 5) and 0.02 ng (lanes 3 and 6). Primers for
TMS1 (lanes 1–3) and estrogen receptor a promoter A (lanes 4–7) were used.
Lane 7, undigested T47D DNA was used as a control. TMS1 promoter is
methylated (bands in digested samples), while estrogen receptor a promoter
A is unmethylated (no bands in digested samples and a band in undigested
sample).
Table 1. Results of MSRE-PCR and the template status
PCR product in Template status
Undigested control MSRE digested sample
Present Present Methylated
Present Absent Unmethylated
Absent Absent Deleted
a
aDeletion of the corresponding fragment has to be verified by an alternative
approach.
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of MCF-7 was added as a genomic equivalent of seven cells
(42 pg), and one-third of the material was used for PCR after
digestion and puriﬁcation. No product was observed when
MCF-7 DNA was omitted from the reaction (lanes 2 and 4),
whereas addition of this DNA before the digestion allowed
formationofaband(lanes1and3);thus DNAfromseven cells
(42 pg) is sufﬁcient for MSRE-PCR, while one-third of that
amount (14 pg) is sufﬁcient for PCR-based detection.
DISCUSSION
In this report we describe the development and validation of
a technique for rapid DNA methylation analysis in a user-
deﬁned set of genes, which is based on extensive digestion
Table 2. DNA methylation in promoters of MDA-MB-231, MCF-7 and T47D:
comparison of MSRE-PCR with available data
Gene MDA MCF-7 T47D Reference
14-3-3s M
b M
b M
a (36)
Apaf-1 M M UM NF
BRCA1 M
b,c UM
a,c UM
b,c (37),(38)
Calcitonin M M UM NF
Caspase-8 UM UM M NF
CycD2 M
c M
c M
a (40)
DAPK UM
a,c,b M
c,c,c UM
a,c,c (41),(37),(38)
E-cadherin M
a,c,c UM
c,c,c UM
c,c,c (42),(38),(39)
EDNRB M M UM NF
EP300 UM UM UM NF
ERa-B(dist) M
c M
c M
c (43)
ERa-A(prox) M
c UM
c UM
c (43)
Fas UM UM UM NF
FHIT UM UM UM NF
GPC3 M
c M
a UM
b (37)
GR UM UM M NF
GSTP1 M
c M
c M
b (38)
HIC-1 M M M NF
HIN-1 M
b M
c M
a (44)
hMLH1 UM
c UM
c UM
c (38)
ICAM-1 M M M NF
MCT1 UM UM UM NF
MDGI M
c M
c M
a (45)
MDR1 M M M NF
MGMT UM
b UM
c UM
c (38)
MCJ UM UM UM NF
MUC2 M M M NF
MYF3/MYOD1 M M UM NF
p15 INK4B D
c D
c UM
b (38)
p16INK4A D
b,c D
a,b M
c,c (37),(38)
p21WAF1 UM UM UM NF
p27Kip1 M M M NF
p57Kip2 UM UM M NF
p73 M
c M
b M
b (38)
PAX5 M
c UM
c M
c (46)
PR M M UM NF
RANKL/TRANCE M M UM NF
Rassf1a M
c,c M
a,c M
c,c (37),(38)
RB1 UM UM UM NF
RFC M
c UM
c UM
a (47)
RIZ1 M
c UM
c M
b (48)
S100A2 M M M NF
SOCS-1 UM UM UM NF
SRBC UM
a M
c M
a (49)
SYK M
a M
b UM
c (50)
TES UM
a M
c M
a (51)
THBS1 UM
c UM
c UM
c (38)
TMS1 M
c M
b M
c (52)
uPA UM
b UM
a M
c (37)
VHL UM UM UM NF
aUntested in paper(s) referenced.
bDifferent result.
cIdentical result.
NF, no references found.
Results from two or more papers are separated with a slash (/).
A
B
C
Figure 2. Validation of MSRE-PCR results with selected genes. (A)
Methylation-specificPCR(MSP)assayoffourgenesinMCF-7cells(duplicate
reactions for each gene). Primers for unmethylated (U) and methylated (M)
DNA of corresponding CpG islands were used. Fragments amplified for MSP
arelocatedwithinregionsanalyzedbyMSRE-PCR.(B)Bisulfitesequencingof
a calcitonin promoter fragment located within a larger fragment used for
MSRE-PCR. Probability of methylation for each of 19 CpG dinucleotides
for MCF-7 (open squares)and T47D (filled squares) is plotted. Vertical arrows
mark the position of CpG dinucleotides; arrowheads indicate CpG dinucleo-
tides within the Hin6I recognition site. Horizontal arrows mark the position of
PCR primers for MSRE-PCR (dashed arrows, primers A and B) and primers
for amplification of bisulfite-modified DNA (dotted arrows, primers a and b).
(C) NorthernblotanalysisofgeneexpressioninMCF-7,T47DandMDA-MB-
231 cells. b-Actin was used as a loading control.
Figure 3. Sensitivity of MSRE-PCR assay for heterogeneous genomic DNA.
MSRE-PCRcansuccessfullyidentifymethylatedfragmentsinamixedsample.
GenomicDNAofT47D(2.6ng,lanes1,2;or1.3ng,lanes3,4)wasmixedwith
42 pg of MCF-7 genomic DNA (lanes 1 and 3) before digestion with Hin6I.
Control samples (lanes 2 and 4) contained only T47D DNA. After digestion,
DNA was purified and one-third of it was used for PCR with RANKL/
TRANCE primers; RANKL/TRANCE is unmethylated in T47D and methy-
lated in MCF-7. Digestion, purification and PCR were performed as described
in Materials and Methods.
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enzyme and PCR ampliﬁcation of surviving fragments. A
fragment will be designated ‘unmethylated’ if no PCR product
is observed after digestion; alternatively, the fragment will be
called ‘methylated’ if it can be ampliﬁed after digestion. In
MSRE-PCR, methylation of restriction sites determines the
result of the assay: if all sites are methylated the fragment
will be scored as methylated even if all the CpGs outside of
Hin6I sites are unmethylated. Conversely, a single unmethyl-
ated recognition site within the fragmentcan cause elimination
of the template, and the whole fragment will be scored as
unmethylated. Thus, MSRE-PCR extrapolates results of a
limited number of sites for the whole fragment.
This feature of MSRE-PCR is similar to almost every
method of methylation analysis: MSP (19) evaluates methyla-
tion status of primer-binding sites to make a conclusion
regarding the complete ampliﬁed region; COBRA (23) tests
restriction sites left unmodiﬁed by bisulﬁte treatment;
MethyLight (24) detects methylation in 1–5 CpG sites covered
by primers and probe; QAMA (25) measures methylation in
a 14 bp fragment covered by a TaqMan probe; MethylQuant
(26) assays methylation of a single cytosine in bisulﬁte-
modiﬁed DNA. It appears that bisulﬁte sequencing (27) is
the only technique that provides the methylation proﬁle of
each and every cytosine within the fragment.
Although similar to bisulﬁte treatment-based methods of
methylation analysis in evaluating methylation in a limited
number of sites, MSRE-PCR allows simple multiplexing and
avoids some of the problems inherent in bisulﬁte conversion,
in particular the poorly controlled efﬁciency of modiﬁcation,
which can be incomplete owing to incomplete denaturation or
partial renaturation of DNA during treatment (28). Compre-
hensive modiﬁcation of unmethylated cytosines is required for
correct readout, which can be inﬂuenced by various factors
(28,29), including DNA apurinization during bisulﬁte treat-
ment (30). Downstream differentiation of the methylated ver-
sus unmethylated sequence in many bisulﬁte-based methods
requires two pairs of primers and two PCR reactions for each
potentially methylated fragment (19), which reduces the
throughput of MSP and similar techniques, making screening
of clinical samples more labor-intensive. Finally, the yield of
each product depends on the quality of the corresponding
primers and can result in biased PCR if the ampliﬁcation
efﬁciency is different (31).
The rationale behind the use of MSRE is elimination of
non-methylated templates, which allows a single-step detec-
tion of templates that survived MSRE digestion. This rationale
was used by Singer-Sam and colleagues (16,17), who treated
genomicDNAwith HpaII andwereable touseHpaIIdigestion
with subsequent PCR ampliﬁcation to analyze DNA methyla-
tion in the mouse H-7 locus (16). In our case, however, HpaII
repeatedly produced incomplete digestion in an overwhelming
majority of samples (data not shown), probably as a result of
increased sensitivity of the assay procedure. This may be due
to speciﬁc features of HpaII, a type IIe restriction enzyme,
which contains two recognition site-binding pockets, only one
of which is catalytically active (32).
Among several methylation-sensitive enzymes that we
tested, Hin6I (recognition sequence GCGC) proved to be
the most robust, with good survival in the reaction at 37C
(data not shown) and ample activity on diluted samples
(digestion of 100 pg of pUC19 in 50 mL reaction, Figure 1B).
In our hands <5% of treated samples fail the pUC19 quality
control step (data not shown), making it sufﬁcient for practical
applications.
Once the MSRE treatment step has been successfully
performed, ampliﬁcation of remaining templates can be done
in a multiplexed format using gene-speciﬁc primers. Primers
were designed to amplify fragments of corresponding CpG
islands of 120–560 bp, with the vast majority of them
containing no more than six and no fewer than two sites for
Hin6I. Within this range and using the digestion conditions
described in Materials and Methods, the chance of scoring any
given fragment as methylated did not depend on the number
of Hin6I sites (46% of all fragments with two and 49% of
fragments with six sites were scored as methylated; data
not shown).
We have observed three types of results using this assay:
presence or absence of a band in the sample with MSRE-
treated template denotes either resistance or sensitivity of
the corresponding template fragment to MSRE, and therefore
either presence or absence of methylation (Table 1). The third
outcome, absence of PCR products in both control and MSRE-
treated samples, can be interpreted as a homozygous dele-
tion of a corresponding promoter region. This outcome was
observed in the case of p16Ink4a (Figure 1C and Table 2),
which was consistent with the deletion of this gene demon-
strated for MCF-7 and MDA-MB-231 by several investigators
(33,34). On the other hand, Musgrove and colleagues (33) did
not ﬁnd the deletion of p15Ink4b in MCF-7, and results
obtained by MSRE-PCR (Figure 1C and Table 2) might reﬂect
genomic variations in different MCF-7 cell lines (35). Another
explanation—single nucleotide polymorphism in a primer-
binding site—has to be considered as well.
Validation of the assay with breast cancer cell lines demon-
strated a very good match between our data and results from
different previously published studies (see Table 2). For the
vast majority of the promoters examined, MSRE-PCR results
were exactly identical to those obtained with other methods.
In some cases, observed differences depend upon the choice
of the DNA region analyzed [e.g. ﬁrst exon of 14-3-3s in (36)
versus promoter region in our work] or by variability of cancer
cell lines [e.g. methylation of uPA promoter in MDA-MB-231
described in (37) versus unmethylated status and expression of
this gene in our work; see Table 2 and Figure 2C].
One of the advantages of MSRE-PCR is a side-by-side
comparison between control (undigested) and experimental
(digested) samples even for very low amounts of starting DNA
(Figure1D). Direct comparison increasesthe reliabilityofdata
by reducing false-negative readings, which are sometimes
observed with methylation target arrays (MTAs) and MSP
assays [e.g. p16Ink4a in MDA-MB-231 scored as unmethyl-
ated in (37) and (38), whereas it is deleted in at least some
variants of this cell line (33,34)].
In most cases the MSRE-PCR data (Table 2) and MSP
results for the same set of genes (37–39) are identical,
despite the fact that MSP is designed to detect methylation
in relatively short fragments corresponding to primer-binding
sequences (19), whereas MSRE-PCR detects methylation in
a region ﬂanked by selected primers (see Materials and
Methods). Whentriedsidebyside, MSPandMSRE-PCRprod-
uce exactly the same results for the genes tested (Figure 2A).
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methods, MSRE-PCR evaluates DNA methylation in a relat-
ively few sites located within the MSRE recognition sequence.
This feature of MSRE-PCR is illustrated by bisulﬁte sequen-
cing of calcitonin promoter in T47D and MCF-7 (Figure 2B):
although the overall probability of at least one cut is very high
for T47D (e.g. the last CpG site within the GCGC sequence is
unmethylated in all sequenced clones, Figure 2B), the same is
not true for MCF-7 (relevant CpG sites have at least 90%
methylation probability, Figure 2B). Consequently, calcitonin
promoter is scored as methylated in MCF-7 and as unmethyl-
ated in T47D by MSRE-PCR (Table 2), although methylation
of non-Hin6I CpG is relatively high in T47D cells.
Despite this limitation a good correlation was observed
between MSRE-PCR data and mRNA expression examined
by northern blot hybridization (Figure 2C), when promoter
methylation always predicted the absence of corresponding
mRNA. Importantly,the opposite is not true, because methyla-
tion is but one mechanism of negative promoter regulation,
e.g. lack of calcitonin expression in T47D (Figure 2C) and
unmethylated status of its promoter (Figure 2B and Table 2).
Probably the most important feature of the MSRE-PCR
assay is its ability to detect promoter methylation in hetero-
geneous samples, even whenmethylated sequences representa
small fraction of the overall specimen. In our hands the assay
could detect the presence of 42 pg of MCF-7 genomic DNA,
which contains methylated promoter of RANKL/TRANCE,
against the background of 2.6 ng of T47D genomic DNA,
where the same promoter is unmethylated (Figure 3). Simple
calculations indicate that the assay has sufﬁcient power
to detect 42:2600 · 100% = 1.6% of methylated templates
against the background of 98.4%, or, taking into account
that a genomic equivalent of 7 cells (42 pg) is sufﬁcient
to detect methylation in a heterogeneous mixture, 350 cells
(7 · 50) from a clinical sample will be sufﬁcient to detect
methylation. Since only one-third of the sample was used
for PCR, the demonstrated sensitivity of the assay is at least
2 cells per 100 cells in the sample. We believe that ﬁne needle
biopsy or a similar method will provide sufﬁcient material for
the assay at this level of sensitivity.
For clinical applications where the primary goal is differ-
entiation between normal and cancerous tissue this level of
sensitivity can be unsafe. For example, heterogeneity of the
sample (e.g. presence of stromal cells), insufﬁciently clean
genomic DNA that cannot be digested, PCR contamination
or incomplete digestion will cause overdetection of methyl-
ated sequences. We have already encountered this situation
with formalin-ﬁxed parafﬁn-embedded samples from breast
cancer patients, when the vast majority of analyzed genes
was scored as methylated and could not be used for differen-
tiation of cancerous samples. Apparently, this can be carried
out by scoring unmethylated genes, where there is no danger
of overdetection by MSRE-PCR (manuscript in preparation);
further studies with a large cohort of patients will test this
conclusion.
Overall, MSRE-PCR data for cultured breast cancer cells
are virtually identical to data obtained with other methods.
MSRE-PCR requires a very small amount of starting material
and can be used with heterogeneous samples, suggesting that
it can be further developed for high-throughput analysis of
clinical material.
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